HPV-Infektion und Zervixkarzinom - Epidemiologie, Nachweis und Immunologie

Zusammenfassung

Bestimmte molekulargenetisch definierte Typen von humanen Papillomviren (HPV) verursachen in Interaktion mit anderen Kofaktoren das Zervixkarzinom. Alle bisher identifizierten Risikofaktoren für Neoplasien der cervix uteri verlieren im Vergleich mit HPV an Bedeutung. Neben HPV ist eine bisher noch nicht klassifizierte genetische Prädisposition wichtig. Der Nachweis von HPV im Abstrich erfolgt durch Identifizierung der Virus-DNA, wobei auf PCR basierende Verfahren die höchste Spezifität besitzen. Im Moment laufen erste Impfstudien mit therapeutischen Impfstoffen und Studien zur prophylaktischen Vakzinierung sind in Planung.

HPV and cervical cancer: Epidemiology, detection and immunological aspects

Summary

Certain molecularly defined types of human papillomaviruses (HPV) induce, by interaction with additional cofactors, cervical cancer. In comparison to infection with HPV, all risk factors identified to date are less important. In addition to HPV a not yet classified genetic predisposition is important. Identification of HPV in cervical smears is done by detection of viral DNA. PCR based methods have the highest specificity. Currently, first vaccination studies with therapeutic vaccines are performed and phase I/II trials for prophylactic vaccination show promising results.

Zervixkarzinom - Epidemiologie - HPV-Nachweis - Immuntherapie

Cervical cancer - epidemiology - HPV detection - immuno therapy

Literatur

• 1 Altmann A, Jochmus-Kudielka I, Frank R, Gausepohl H, Moebius U, Gissmann L, Meuer S C. Definition of immunogenic determinants of the human papillomavirus type 16 nucleoprotein E7.  Eur J Cancer. 1992;  28 326-333
• 2 ALTS Group . Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group [see comments].  J Natl Cancer Inst. 2000;  92 397-402
• 3 Anonymous. Cancer of the cervix: death by incompetence [editorial].  Lancet. 1985;  II 363-364
• 4 Statistisches Landesamt Saarland .Morbidität und Mortalität an bösartigen Neubildungen im Saarland 1992. 1995; Sonderheft 180
• 5 Barrasso R, De Brux J, Croissant O, Orth G. High prevalence of papillomavirus-associated penile intraepithelial neoplasia in sexual partners of women with cervical intraepithelial neoplasia.  N Engl J Med. 1987;  317 916-923
• 6 Bauer H M, Ting Y, Greer C E, Chambers J C. et al . Genital human papillomavirus infection in female university students as determined by a PCR-based method [see comments].  JAMA. 1991;  265 472-477
• 7 Bauer H M, Hildesheim A, Schiffman M H. et al . Determinants of genital human papillomavirus infection in low-risk women in Portland, Oregon.  Sex Transm Dis. 1993;  20 274-278
• 8 Benton C, Shahidullah H, Hunter J AA. Human papillomavirus in the immunosuppressed.  Papillomavirus Report. 1992;  3 23-26
• 9 Borysiewicz L K, Fiander A, Nimako M. et al . A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer [see comments].  Lancet. 1996;  347 1523-1527
• 10 Bosch F X, Manos M M, Munoz N. et al . Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group.  J Natl Cancer Inst. 1995;  87 796-802
• 11 Bryans R E, Boyles D A, Fidler H K. The influence of a cytological screening program upon the incidence of invasive aquamous cell carcinoma of the cervix in British Columbia.  Am J Obstet Gynecol. 1964;  88 898
• 12 Campo M S, Grindlay G J, O'Neil B W, Chandrachud L M, McGarvie G M, Jarrett W F. Prophylactic and therapeutic vaccination against a mucosal papillomavirus.  J Gen Virol. 1993;  74 945-953
• 13 Chandrachud L M, O'Neil B W, Jarrett W F, Grindlay G J, McGarvie G M, Campo M S. Humoral immune response to the E7 protein of bovine papillomavirus type 4 and identification of B-cell epitopes.  Virology. 1994;  200 98-104
• 14 Christensen N D, Kreider J W, Kan N C, DiAngelo S L. The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes.  Virology. 1991;  181 572-579
• 15 Coleman N, Birley H D, Renton A M, Hanna N F, Ryait B K, Byrne M, Taylor-Robinson D, Stanley M A. Immunological events in regressing genital warts.  Am J Clin Pathol. 1994;  102 768-774
• 16 de Gruijl T D, Bontkes H J, Stukart M J. et al . T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection.  J Gen Virol. 1996;  77 2183-2191
• 17 Fredericks B D, Balkin A, Daniel H W, Schonrock J, Ward B, Frazer I CH. Transmission of human papillomaviruses from mother to child [see comments].  Aust NZ J Obstet Gynaecol. 1993;  33 30-32
• 18 Hall S, Lorincz A, Shah F, Sherman M E, Abbas F, Paull G, Kurman R J, Shah K V. Human papillomavirus DNA detection in cervical specimens by hybrid capture: correlation with cytologic and histologic diagnoses of squamous intraepithelial lesions of the cervix.  Gynecol Oncol. 1996;  62 353-359
• 19 Halpert R, Fruchter R G, Sedlis A, Butt K, Boyce J G, Sillman F H. Human papillomavirus and lower genital neoplasia in renal transplant patients.  Obstet Gynecol. 1986;  68 251-258
• 20 Handley J, Dinsmore W, Maw R, Corbell R, Burrows D, Bharucha H, Swann A, Bingham A. Anogenital warts in prepubertal children; sexual abuse or not? [see comments].  Int J STDAIDS. 1993;  4 271-279
• 21 Hildesheim A, Schiffman M H, Gravitt P E. et al . Persistence of type-specific human papillomavirus infection among cytologically normal women [see comments].  J Infect Dis. 1994;  169 235-240
• 22 Jacobs M V, Snijders P J, van der Brule A J, Helmerhorst T J, Meijer C J. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay meth rapid detection of 14 high risk human papillomavirus genoty cervical scrapings.  J Clin Microbiol. 1997;  35 791-795
• 23 Jarrett W F, Smith K T, O'Neil B W. et al . Studies on vaccination against papillomaviruses: prophylactic and therapeutic vaccination with recombinant structural proteins.  Virology. 1991;  184 33-42
• 24 Jochmus I, Osen W, Altmann A. et al . Specificity of human cytotoxic T lymphocytes induced by a human papillomavirus type 16 E7-derived peptide.  J Gen Virol. 1997;  78 1689-1695
• 25 Kadish A S, Romney S L, Ledwidge R. et al . Cell-mediated immune responses to E7 peptides of human papillomavirus (HPV) type 16 are dependent on the HPV type infecting the cervix whereas serological reactivity is not type-specific.  J Gen Virol. 1994;  75 2277-2284
• 26 Knowles G, O'Neil B W, Campo M S. Phenotypical characterization of lymphocytes infiltrating regressing papillomas.  J Virol. 1996;  70 8451-8458
• 27 Koutsky L A, Galloway D A, Holmes K K. Epidemiology of genital human papillomavirus infection.  Epidemiol Rev. 1988;  10 122-163
• 28 Koutsky L A, Holmes K K, Critchlow C W. et al . A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection.  N Engl J Med. 1992;  327 1272-1278
• 29 Ley C, Bauer H M, Reingold A, Schiffman H M, Chambers J C, Tashiro C J, Manos M M. Determinants of genital human papillomavirus infection in young women [see comments].  J Natl Cancer Inst. 1991;  83 997-1003
• 30 Lin Y L, Borenstein L A, Selvakumar R, Ahmed R, Wettstein F O. Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus.  Virology. 1992;  187 612-619
• 31 Magnusson P K, Sparen P, Gyllensten U B. Genetic link to cervical tumours [letter].  Nature. 1999;  400 29-30
• 32 McGarvie G M, Grindlay G J, Chandrachud L M, O'Neil B W, Jarrett W F, Campo M S. T-cell responses to BPV-4 E7 during infection and mapping of T-cell epitopes.  Virology. 1995;  206 504-510
• 33 Moscicki A B, Palefsky J, Gonzales J, Schoolnik G K. Human papillomavirus infection in sexually active adolescent females: prevalence and risk factors.  Pediatr Res. 1990;  28 507-513
• 34 Möhner M. Krebsinzidenz in der DDR 1988/1989. In: Anonymous (ed) Atlas der Krebsinzidenz in der DDR 1961-1989: Gemeinsames Krebsregister der Länder Berlin, Brandenburg, Mecklenburg-Vorpommern, Sachsen-Anhalt, Thüringen und des Freistaates Sachsen beim Bundesgesundheitsamt. Ullstein Mosby, Berlin 1994; 1-4047
• 35 Munoz N, Bosch F X, de Sanjose S. et al . The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain.  Int J Cancer. 1992;  52 743-749
• 36 Nindl I, Benitez-Bribiesca L, Berumen J. et al . Antibodies against linear and conformational epitopes of the human papillomavirus (HPV) type 16 E6 and E7 oncoproteins in sera of cervical cancer patients.  Arch Virol. 1994;  137 341-353
• 37 Nonnenmacher B, Hubbert N L, Kirnbauer R. et al . Serologic response to human papillomavirus type 16 (HPV-16) virus-like particles in HPV-16 DNA-positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain.  J Infect Dis. 1995;  172 19-24
• 38 Oriel J D. Natural history of genital warts. 1971 [classical article] [see comments].  Sex Transm Infect. 2000;  76 (Suppl 1) S 21
• 39 Palefsky J M, Gonzales J, Greenblatt R M, Ahn D K, Hollander H. Anal intraepithelial neoplasia and anal papillomavirus infection among homosexual males with group IV HIV disease.  JAMA. 1990;  263 2911-2916
• 40 Peters R K, Chao A, Mack T M, Thomas D, Bernstein L, Henderson B E. Increased frequency of adenocarcinoma of the uterine cervix in young women in Los Angeles County.  J Natl Cancer Inst. 1986;  76 423-428
• 41 Ponten J, Adami H O, Bergström R. et al . Strategies for global control of cervical cancer [see comments].  Int J Cancer. 1995;  60 1-26
• 42 Resnick R M, Cornelissen M T, Eichinger G H. et al . Detection and typing of human papillomavirus in archival cervical cancer specimens by DNA amplification with consensus primers.  J Natl Cancer Inst. 1990;  82 1477-1484
• 43 Ressing M E, Sette A, Brandt R M. et al . Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides.  J Immunol. 1995;  154 5934-5943
• 44 Ressing M E, van Driel W J, Celis E. et al . Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope.  Cancer Res. 1996;  56 582-588
• 45 Richart R M. Cervical intraepithelial neoplasia.  Pathol Annu. 1973;  8 301-328
• 46 Roman A, Fife K. Human papillomavirus DNA associated with foreskins of normal newborns.  J Infect Dis. 1986;  153 855-861
• 47 Schiffman M H. Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia.  J Natl Cancer Inst. 1992;  84 394-398
• 48 Schiffman M H, Bauer H M, Hoover R N. et al . Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia [see comments].  J Natl Cancer Inst. 1993;  85 958-964
• 49 Schiffman M H, Herrero R, Hildesheim A. et al . HPV DNA testing cervical cancer screening: results from in a high province of Costa Rica.  JAMA. 2000;  283 87-93
• 50 Schneider A, Kirchmayr R, de Villiers E M, Gissmann L. Subclinical human papillomavirus infections in male sexual partners of female carriers.  J Urol. 1988;  140 1431-1434
• 51 Schneider A, Schlunck G. Detection and typing of genital papillomaviruses: nucleic acid hybridization and type-specific antigen detection. In: Gross G, Jablonska S, Pfister H, Stegner HE, (Eds). Genital papillomavirus infections: Advances in modern diagnosis and therapy. Springer, Heidelberg, New York, Tokyo 1989; 69-86
• 52 Schneider A. Pathogenesis of genital HPV infection.  Genitourin Med. 1993;  69 165-173
• 53 Schneider A, Wagner D. Infektionen der Frau mit genitalem humanem Papillomvirus.  Dtsch Ärztebl. 1993;  90 730-732
• 54 Schneider A, Dürst M, Jochmus I, Gissmann L. Epidemiologie, Äthiologie und Prävention des Zervixkarzinoms.  Onkologe. 1998;  4 110-123
• 55 Schwartz S M, Weiss N S. Increased incidence of adenocarcinoma of the cervix in young women in the United States.  Am J Epidemiol. 1986;  124 1045-1047
• 56 Sedlacek T V, Lindheim S, Eder C, Hasty L, Woodland M, Ludomirski A, Rando R F. Mechanism for human papillomavirus transmission at birth.  Am J Obstet Gynecol. 1989;  161 55-59
• 57 Selvakumar R, Borenstein L A, Lin Y L, Ahmed R, Wettstein F O. Immunization with nonstructural proteins E1 and E2 of cottontail rabbit papillomavirus stimulates regression of virus-induced papillomas.  J Virol. 1995;  69 602-605
• 58 Selvakumar R, Schmitt A, Iftner T, Ahmed R, Wettstein F O. Regression of papillomas induced by cottontail rabbit papillomavirus is associated with infiltration of CD8+ cells and persistence of viral DNA after regression.  J Virol. 1997;  71 5540-5548
• 59 Snijders P J, van den Brule A J, Schrijnemakers H F, Snow G, Meijer C J, Walboomers J M. The use of general primers in the polymerase chain reaction permits the detection of a broad spectrum of human papillomavirus genotypes.  J Gen Virol. 1990;  71 173-181
• 60 Sparen P, Gustafsson L, Friberg L G, Ponten J, Bergstrom R, Adami H O. Improved control of invasive cervical cancer in Sweden over six decades by earlier clinical detection and better treatment.  J Clin Oncol. 1995;  13 715-725
• 61 St Louis M E, Icenogle J P, Manzila T, Kamenga M, Ryder R W, Hayward W L, Reeves W C. Genital types of papillomavirus in children of women with HIV-1 infection in Kinshasa, Zaire.  Int J Cancer. 1993;  54 181-184
• 62 Steele J C, Stankovic T, Gallimore P H. Production and characterization of human proliferative T-cell clones specific for human papillomavirus type 1 E4 protein.  J Virol. 1993;  67 2799-2806
• 63 van Wijngaarden W J, Duncan I D, Hussain K A. Screening for cervical neoplasia in Dundee and Angus: 10 years on.  Br J Obstet Gynaecol. 1995;  102 137-142
• 64 Vermund S H, Kelley K F, Klein R S, Reingold A R, Schreiber K, Munk G, Burk R D. High risk of human papillomavirus infection and cervical squamous intraepithelial lesions among women with symptomatic human immunodeficiency virus infection.  Am J Obstet Gynecol. 1991;  165 392-400
• 65 Walboomers J M, Jacobs M V, Manos M M. et al . Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.  J Pathol. 1999;  189 12-19
• 66 Wright T CJ, Lörincz A, Ferris D G, Richart R M, Ferenczy A, Mielzynka I, Borgotta L. Reflex human papillomavirus deoxyribonucleic acid testing in women with abnormal Papanicolaou smears.  Am J Obstet Gynecol. 1998;  178 962-966
• 67 zur Hausen H, Richart R M. IARC monographs on the evaluation of carcinogenic risks to humans. Human papillomaviruses Lyon, Frankreich.  1995;  64 277-28?